



**Europass  
Curriculum Vitae**



**Personal information**

Surname / name **OPOCHER ENRICO**

Address(es)

Telephone(s)

Mobile:

Fax(es)

E-mail



Nationality Italian

Date of Birth

Gender Male

**Occupational field** **PediatricOncologistTenured Staff Member, UOC Oncoematologia  
pediatrica, Azienda Ospedaliera di Padova**

**Medical licence** **(Italia) n.ordine dei Medici e Chirurghi di Padova, PD09875**  
**(UK) General Medical Council (GMC)full registration with Licence to Practise  
n 7621120**

<b>Previous Work experiences</b>	Locum Consultant in the paediatric oncology group, Blood, Cell, and Cancer Dep, Blood Cell, and Cancer Department, Great Ormond Street Hospital-London, UK
Dates	July 2018-August 2021
Occupation and position held	Locum consultant
Main activities and responsibilities	<p>Full time work as part of a team of consultant oncologists specialising in management of patients with CNS tumours and sother solid tumour malignancies, with particular expertise in treating infants &lt; 1 year (main referral centre within greater London area) AND special interest in CNS tumours (low grade glioma-LGG, other brain tumours), retinoblastoma (RB), LCH, liver, and renal tumours, with inpatient attending weeks (1:7) and outpatient clinics (2 days per week), and participating in the consultant night-and weekend on call rota for oncology.</p>
	Tenured staff-Pediatric Oncology Department, AziendaOspedaliera di Padova, Italy, November 2015-July 2018
	January October 2012
	Resident Senior at the Institute Gustave Roussy (IGR), Villejuif, France
	Participation at the daily clinical activity of the Pediatric Oncology Department (day care and Hospital),
Dates	
Dates	2012 Jan-Oct
Occupation or position held	<b>3 years PhD in pediatric hematology-oncology</b> , with clinical and researches activities in the pediatric oncology-hematology Division of the Padua University Hospital, Italy since January 2011, with a particular interest in solid tumors and brain tumors
Main activities and responsibilities	<p><b>Member</b> of the pediatric oncology team of Padua, with a particular interest in clinical research on Low-grade glioma</p> <p><b>Clinical research</b> focused on new studies on brain tumors (HGG, LGG, etc...) as co-investigator within the Innovative Therapy for Children with Cancer (ITCC) Padua Group with G.Bisogno.</p>

**Clinical research** in the development of future International Cooperative Studies on solid tumors (SIOP-LGG 201X)

**Main Author** of peer-review papers on pediatric neuro-oncology subjects with particular experience on visual outcome of children with low grade gliomas and Neurofibromatosis type 1 (see bibliography)

**Reviewer** of international peer-review Journals (Pediatrics)

**Author of oral and poster presentations** at international pediatric oncology congresses and meetings (SIOP-Geneva 2005 SIOP-LGG meetings), and at national AIEOP-Brain Tumors working groups meetings (2008 & 2011-Genova), ISPNO 2012

Member of the **SIOP Young Investigator Group** since November 2017 with a specific responsibility on the mentorship program and the educational day planning

Name and address of Employer

**Prof. A. Biffi**, MD, PhD, PhD Hematology-oncology program director and next head of the pediatric Hematology-oncology division, Department of Pediatrics, Padua, Italy

**Gianni Bisogno**, MD, Pediatric Oncology Unit, Department of Pediatrics, Padua

## Education and training

type Faculty of Medicine and Surgery, University of Padua, Italy  
dates October 1999 -October 2005

title of qualification awarded **Degree in Medicine and Surgery (19/10/2005)**

type 5 years-Pediatric Residency, at the Pediatric Department of Padua, with 2 years elective training in Pediatric Intensive Care Unit (PICU) and Pediatric Hematology-Oncology (1 year+ 1 year)

Dates From January 2005 to December 2010

Title of qualification awarded **Pediatrician(12/Jan/2011)**

Principal subjects/occupational skills covered

**Clinical activities within the Pediatric Department** (Hematology-Oncology Division, Emergency Room, PICU) with particular interest in children with Central Nervous System brain tumor diagnosis, post surgical & intensive care, tumor staging and treatment strategies and follow-up

Name and type of organisation providing education and training

Pediatric Hematology-Oncology Division, Department of Pediatrics, Padua University, Italy

Mother tongue(s)

**Italian**

Other language(s)

Self-assessment  
*European level (\*)*

Understanding		Speaking		Writing
Listening	Reading	Spoken interaction	Spoken production	
C2	C2	C1	C1	B2
A2	A2	A2	A2	A1

**English**

**French**

(\*) [Common European Framework of Reference for Languages](#)

Other skills and competences

Participation at the Course **ITCC-ENCCA rational drug development in pediatric oncology**, Rome May 2011

**Evidence-based Medicine** principle and methodology experience in collaboration with the Cochrane Childhood Cancer Group (with L.K. Kremer) the Italian Group of Evidence-Based Medicine (GIMBE, N. Cartabellotta) and as member of the pediatric Journal Club Committee, Padua

Laboratory experience and training in the Collaborative project on **Newborn screening** with Tandem Mass Spectrometry, with P.Rinaldo, Mayo Clinic, Rochester, Minnesota, USA.

<b>Participation to clinical trials</b>	<b>Sub-investigator of phase II sponsored clinical trials</b>  -HERBY, a phase II randomised trial of bevacizumab in addition to standard of care in children and adolescent with HGG (Roche, PI J.Grill) - BERNIE, a phase II randomised trial of bevacizumab in addition to chemotherapy in children with metastatic sarcoma -SCOUT: a phase I/II trial of Larotrectinib in infants and children with NTRK altered solid tumors -member of the Innovative Treatment for Children with Cancer (ITCC)
<b>Good Clinical Practice Certificate</b>	<b>03/11/2020 (expiry 03 nov 2023)</b>
<b>PBLS-D</b>	Last PBLS training on the 2 <sup>nd</sup> of August 2018, at GOSH (UK), expected refresh course on the 2-3 <sup>rd</sup> of nov 2021 (Padova)
<b>PALS</b>	PALS executor and trainee, last certificate in May 2017, with new certificate expected by the 25 <sup>th</sup> of Nov 2021
<b>Annexes</b>	<b>List of Publications</b>

#### List of Publications:

1. **Opocher E**, Kremer L.C.M, et Al, Prognostic factors for progression of childhood optic pathway glioma: a systematic review, *European Journal of Cancer* 2006, 42; 1807-1816
2. Dalla Via, **Opocher E**. et Al, Visual Outcome of a cohort of children with neurofibromatosis type 1 and optic pathway glioma followed by a pediatric neuro-oncology program, *Neuro-Oncology*, 2007 October, 430-437
3. **E. Opocher**, S. Bressan, M. Gabelli: "E' possibile che l'assunzione di paracetamolo sia un fattore di rischio per lo sviluppo di asma ?", *Pneumologia Pediatrica* 2008, 32: 45-49
4. S. Stefani, **E. Opocher** et Al: Morsi di mezza estate. *Medico e Bambino pagine elettroniche*, 2008; 11 (6)
5. **E. Opocher**, M. Balzani et Al: Corticosteroidi per via orale in bambini di età prescolare con wheezing episodico virale: cosa resta di questa terapia ?, *Pneumologia Pediatrica* 2009, 35: 80-83
6. **E. Opocher**: Critical review of "Corticosteroids to prevent extubation failure: a systematic review and meta-analysis. *Intensive Care Med* 2009 June; 35 (6): 997-86", on *The Peds Critical Care Medicine Evidence-based journal Club Review*, 2009
7. **E. Opocher**, G. Bisogno, M. Calderone, P. Drigo: Unusual Neuroimaging in a young boy with cerebral X-linked Adrenoleukodystrophy, *Neuropediatrics* 2010; 41: 66-68
8. Campagna M., **Opocher E**, et Al: Long term visual outcome of optic pathway glioma in a cohort of children without Neurofibromatosis type-1, *Pediatric Blood and Cancer*, Dic 2010
9. *Perilongo G, Opocher E, Viscardi E. Optic, hypothalamic, and thalamic tumors. HandbClinNeurol. 2012;105:607-13.*
10. *Cavicchiolo M.E, Opocher E, Daverio M, Bendini M, Viscardi E, Bisogno G, Perilongo G, Da Dalt L. Diencephalic syndrome assign of tumor progression in a child with neurofibromatosis type 1 and optic pathway glioma: a case report. Childs Nerv Syst. 2013 Oct;29(10):1941-5. doi: 10.1007/s00381-013-2109-5. Epub 2013 Apr 25.*

11. Trevisson E, Cassina M, **Opocher E** et Al, Natural history of optic pathway gliomas in a cohort of unselected patients affected by Neurofibromatosis 1. *J Neurooncol.* 2017 Jun 2. doi: 10.1007/s11060-017-2517-6.
12. Cusinato M, Calvo V, Bisogno G, Viscardi E, Pillon M, **Opocher E**, Basso G, Montanaro M. Attachment orientations and psychological adjustment of parents of children with cancer: A matched-group comparison. *J Psychosoc Oncol.* 2017 Jun 1:0. doi: 10.1080/07347332.2017.1335365.
13. Sperotto F, Bisogno G, **Opocher E**, Rossi S, Rigon C, Trevisson E, Mercolini F. Osteopathia striata with cranial Sclerosis and Wilms tumor: Coincidence or consequence? *Clin Genet.* 2017 Dec;92(6):674-675.
14. Campbell BB, Light N, Fabrizio D, Zatzman M, Fuligni F, de Borja R, Davidson S, Edwards M, Elvin JA, Hodel KP, Zahurancik WJ, Suo Z, Lipman T, Wimmer K, Kratz CP, Bowers DC, Laetsch TW, Dunn GP, Johanns TM, Grimmer MR, Smirnov IV, Larouche V, Samuel D, Bronsema A, Osborn M, Stearns D, Raman P, Cole KA, Storm PB, Yalon M, **Opocher E**, Mason G, Thomas GA, Sabel M, George B, Ziegler DS, Lindhorst S, Issai VM, Constantini S, Toledano H, Elhasid R, Farah R, Dvir R, Dirks P, Huang A, Galati MA, Chung J, Ramaswamy V, Irwin MS, Aronson M, Durno C, Taylor MD, Rechavi G, Maris JM, Bouffet E, Hawkins C, Costello JF, Meyn MS, Pursell ZF, Malkin D, Tabori U, Shlien A. Comprehensive Analysis of Hypermutation in Human Cancer. *Cell.* 2017 Nov 16;171(5):1042-1056
15. Galuppini F, **Opocher E**, Tabori U, Mammi I, Edwards M, Campbell B, Kelly J, Viel A, Quaia M, Rivieri F, D'Avella D, Arcella A, Giangaspero F, Fassan M, Gardiman MP. Concomitant IDH-wildtype glioblastoma and IDH1-mutant anaplastic astrocytoma in a patient with constitutional mismatch repair deficiency syndrome. *Neuropathol Appl Neurobiol.* 2017 Nov 12.
16. Parrozzani R, Miglionico G, Pulze S, Trevisson E, Clementi M, **Opocher E**, Licata V, Viscardi E, Pilotto E, Frizzierol, Midenia E Correlation of peripapillary retinal nerve fibre layer thickness with visual acuity in paediatric patients affected by optic pathway glioma, *Acta Ophthalmol.* 2018 Oct 3. doi: 10.1111/aos.13803

## List of Abstracts

1. Prognostic factors for progression of childhood optic pathway glioma: a systematic review, Oral Presentation at the Congress of the International Society of Pediatric Oncology (SIOP), 2006, Ginevra, Svizzera, Ottobre 2006
2. Functional outcome of children with NF1 and optic pathway glioma: experience of the neuro-oncology program of Padua University, Poster at the Congress of the International Society of Pediatric Oncology (SIOP), 2006, Ginevra, Svizzera, Ottobre 2006
3. Infantile fibretypedisproportion and cardiomyopathy: a rare disorder with a therapeutic dilemma, Poster al Congresso Europeo di terapia intensiva pediatrica e neonatale (ESPNIC), 14-17 Giugno 2009
4. Un disturbo dell'attenzione/iperattività (ADHD) nasconde una forma atipica di X-linked Adrenoleukodistrofia (X-ALD) con diffusione frontale. Un caso clinico, Poster al 65° congresso della Società Italiana di Pediatria (SIP)
5. Visual outcome of children with NF1 and progressive optic pathway glioma treated with chemotherapy: preliminary report from the SIOP-LGG04 study, oral Presentation at the 15<sup>th</sup> International Symposium of Pediatric Neuro oncology (ISPNO), 24-26 Giugno, 2012, Toronto,

Canada

6. Children below the age of two treated for optic pathway glioma: a multinational retrospective multivariate analysis of risk factors, oral presentation at the 15<sup>th</sup> International Symposium of Pediatric Neuro oncology (ISPNO), (ISPNO), 24-26 Giugno, 2012, Toronto, Canada

**Padova, 06/07/2023**

**Enrico Opocher**